Guerbet SA (FRA:4G8)

Market Cap	99.91M -64.8%
Revenue (ttm)	798.67M -6.2%
Net Income	-108.33M
EPS	-8.59
Shares Out	n/a
PE Ratio	n/a
Forward PE	103.84
Dividend	n/a
Ex-Dividend Date	n/a

Volume	75
Open	7.41
Previous Close	7.32
Day's Range	7.41 - 7.41
52-Week Range	7.05 - 21.65
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 28, 2026

About Guerbet

Guerbet SA provides a range of contrast media, medical devices, and digital and AI solutions for diagnostic and interventional imaging worldwide. It offers DOTAREM, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced MRI examinations; Elucirem, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced resonance imaging; UNIK, a diagnostic imaging interconnected solution; and Artirem, a gadoteric acid. The company also provides OptiStar Elite, a dual head contrast delivery system with an ultrasonic motor; ...

• Industry: X-Ray Apparatus and Tubes and Related Irradiation Apparatus
• Founded: 1901
• Employees: 2,746
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4G8

Financial Performance

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error